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 Abstract 
Background. Hippocampal atrophy is a well-known feature of Alzheimer’s disease (AD), but 
sensitivity and specificity of hippocampal volumetry are limited. Neuropathological studies have 
shown that hippocampal subfields are differentially vulnerable to AD; hippocampal subfield 
volumetry may thus prove to be more accurate than global hippocampal volumetry to detect AD. 
Methods. CA1, subiculum and other subfields were manually delineated from 40 healthy controls, 
18 AD, 17 amnestic Mild Cognitive Impairment (aMCI), and 8 Semantic Dementia (SD) patients 
using a previously developed high resolution MRI procedure. Non-parametric group comparisons 
and receiver operating characteristic (ROC) analyses were conducted. Complementary analyses 
were conducted to evaluate differences of hemispheric asymmetry and anterior-predominance 
between AD and SD patients and to distinguish aMCI patients with or without β-amyloid 
deposition as assessed by Florbetapir-TEP. Results. Global hippocampi were atrophied in all three 
patient groups and volume decreases were maximal in the CA1 subfield (22% loss in aMCI, 27% in 
both AD and SD; all p<0.001). In aMCI, CA1 volumetry was more accurate than global 
hippocampal measurement to distinguish patients from controls (areas under the ROC Curve = 0.88 
and 0.76, respectively; p=0.05) and preliminary analyses suggest that is was independent from the 
presence of β-amyloid deposition. In patients with SD, whereas the degree of CA1 and subiculum 
atrophy was similar to that found in AD patients, hemispheric and anterior-posterior asymmetry 
was significantly more marked than in AD with greater involvement of the left and anterior 
hippocampal subfields. Conclusions. The findings suggest that CA1 measurement is more sensitive 
than global hippocampal volumetry to detect structural changes at the pre-dementia stage, although 
the predominance of CA1 atrophy does not appear to be specific to AD pathophysiological 
processes. 
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Abbreviations:  
Aβ = β-amyloid;  
AD = Alzheimer’s Disease;  
aMCI = amnestic Mild Cognitive Impairment;  
ANOVA = ANalysis Of VAriance;  
AUC = Area Under the receiver operating characteristic Curve;  
HC = healthy controls;  
MRI = Magnetic Resonance Imaging;  
NFT = NeuroFibrillary Tangles;  
PET = Positon Emission Tomography;  
ROC = Receiver Operating Characteristic;  
SUVr = Standardized Uptake Value ratio;  
TIV = Total Intracranial Volume. 
  
 1. Introduction 
Hippocampal atrophy is a major feature of Alzheimer’s disease (AD) [1] that strongly correlates 
with AD neuropathology [2,3]. Using MRI, this atrophy is detectable prior to the diagnosis of AD, 
at the stage of amnestic Mild Cognitive Impairment (aMCI) [4,5] or even earlier, in asymptomatic 
elderly up to 10 years before the diagnosis of dementia [6,7]. Hippocampal volume has thus been 
proposed as a neuroimaging biomarker for early AD diagnosis [8,9]. Yet, the accuracy of this 
measurement is limited by a moderate sensitivity and a rather low specificity to AD 
pathophysiological processes [1]. Indeed, hippocampal atrophy has been highlighted in various 
neurological and psychiatric conditions [10], and notably in other neurodegenerative disorders such 
as semantic dementia (SD) [11–15]. 
Interestingly, neuropathological studies have shown a differential vulnerability of hippocampal 
subfields to AD, with CA1 showing the earliest and strongest changes in terms of both 
neurofibrillary tangles (NFT) [16,17] and neuronal loss [18,19]. In vivo measurement of CA1 
atrophy may thus constitute a better surrogate marker for AD pathology than global hippocampal 
volumetry. Recently MRI acquisition and processing techniques have been developed to assess the 
hippocampus in more detail, including high-resolution hippocampus scans allowing visualization 
and measurement of hippocampal subfields [20–22]. 
In this study, we aimed at identifying the pattern of hippocampal subfield atrophy in patients with 
AD, aMCI and SD using a previously developed technique based on high-resolution 3-Tesla-MRI 
and adapted delineation guidelines [23]. In addition we assessed the diagnosis accuracy of these 
measures, hypothesizing that specific measurement of the most vulnerable subfield(s), e.g. CA1, 
would be more accurate than global hippocampal volumetry to detect AD-related hippocampal 
atrophy [20,21]. 
 
 
  
2. Material and methods 
2.1. Participants 
Eighty-three right-handed native French-speaking participants from the IMAP project [23] were 
included in the present study: 40 healthy controls (HC), 17 aMCI patients, 18 AD patients, and 
eight SD patients (see Table 1). They were all aged over 50 years, had at least 7 years of education 
and had no history of alcoholism, drug abuse, head trauma or psychiatric disorder.  
All patients were recruited from local memory clinics and selected according to corresponding 
internationally agreed criteria: Petersen’s criteria for aMCI [24], NINCDS-ADRDA criteria  for 
probable Alzheimer’s disease [25] and Neary et al criteria for SD [26].  
HC were recruited from the community and performed in the normal range on a 
neuropsychological examination assessing multiple domains of cognition including episodic and 
semantic memory, executive and visuo-spatial functions, language and praxis. 
In addition to this clinically based selection, the majority of aMCI and AD patients underwent a 
Florbetapir PET scan allowing to classify them as β-amyloid (Aβ)-positive or Aβ-negative as 
recommended in the new research criteria for AD [8,9] (see sections 2.3.3 and 2.4 below). 
The IMAP Study was approved by regional ethics committee (Comité de Protection des Personnes 
Nord-Ouest III) and is registered with ClinicalTrials.gov (number NCT01638949). All participants 
gave written informed consent to the study prior to the investigation. 
2.2. Neuroimaging data acquisition.  
All participants were scanned on the same MRI and PET cameras at the Cyceron center (Caen, 
France). 
2.2.1. MRI data.  
A high-resolution proton density-weighted MR sequence, perpendicular to the long axis of the 
hippocampus (repetition time/echo time = 3500/19 msec; flip angle = 90°; 13 x 2 mm slices with 2 
 mm gap; in-plane resolution = 0.375 x 0.375 mm) was acquired on a Philips (Eindhoven, The 
Netherlands) Achieva 3T scanner. A sagittal T1-weighted anatomical image was obtained 
beforehand using a 3D fast field echo sequence (repetition time/echo time = 20/4.6 msec; flip angle 
= 20°; 180 x 1 mm slices without gap; in-plane resolution = 1 x 1 mm) for the purpose of PET data 
preprocessing and Total Intracranial Volume (TIV) measurement (see below).  
2.2.2. PET data.  
Florbetapir PET scans were acquired on a Discovery RX VCT 64 PET-CT device (General Electric 
Healthcare) with a resolution of 3.76 x 3.76 x 4.9 mm (field of view = 157 mm). Forty-seven planes 
were obtained with a voxel size of 2.7 x 2.7 x 3.27 mm. A transmission scan was performed for 
attenuation correction before the PET acquisition. Participants underwent a 20-min PET scan, 
starting 50 min after the intravenous injection of ≈ 4 MBq/kg of Florbetapir.  
2.3. Neuroimaging data processing.  
2.3.1. Hippocampal subfield delineation.  
Three regions of interest (subiculum, CA1 and “other” subfields - encompassing CA2-CA3-CA4 
and the dentate gyrus) were delineated on both hippocampi of all individual high-resolution MRI 
images, following guidelines developed in the lab and described in full details elsewhere [23]. 
These guidelines were based on the anatomical description from an atlas of the human 
hippocampus [27]. Delineations were performed on slices perpendicular to the long axis of the 
hippocampus by a single rater, blind to the identity (age, gender, clinical status) of the participants. 
Illustrations are provided in Figure 1 (see also Supplementary Figure 1 for further details and 
additional examples). 
Unlike other groups with comparable high-resolution anisotropic images [20,21] we delineated 
subfields along the head and body of the hippocampus (versus in the body only for these previous 
articles). Yet, because of the difficulty of distinguishing landmarks for subfields delineation in the 
hippocampal head, we only considered 3 regions of interest (therefore combining CA2-3-4 and the 
 dentate gyrus in the same “subfield”) to ensure sufficient reliability and reproducibility (versus 4 or 
5 subfields in previous studies [20,21]). As previously mentioned [20,22], measurements of 
hippocampal subfields not only rely on landmarks derived from anatomical atlases, but also on 
arbitrary rules that are fixed by the investigators to reach a compromise between 
reliability/reproducibility and validity. We acknowledge that existing protocols show differences in 
their definition of hippocampal subfields but, in the absence of direct comparison between in vivo 
imaging methods (ideally including a confrontation to neuropathological gold standard), the 
importance of these variations and their influence on results remains unknown. However, a recently 
formed initiative led by experts in the field is specifically meant to address this issue and to 
potentially develop a unified hippocampal subfield segmentation protocol (to know more about this 
group, visit http://www.hippocampalsubfields.com/ ). 
Moreover, it is to note that high-resolution scans such as those used here are particularly prone to 
motion artifacts. To prevent the rejection of a large proportion of individuals from analyses, a 
procedure was settled to obtain high quality data from all individuals participating to imaging 
studies in our lab (including, but not restricted to the controls and patients from the present article). 
Indeed, a visual quality check was performed immediately after or within a few days of the MRI 
acquisition and was carried out by the same person who analyses the data (RLJ). If image quality 
was considered insufficient for subfield delineation, the scan was repeated within a few weeks 
during a second MRI session (this occurred for about 15-20% of healthy controls and 30-40% of 
the patients included in our total imaging cohort). Rarely, a third scan was proposed. In the end, we 
failed to obtain an image of sufficient quality in some participants (roughly 5-10% of the controls 
and 15-20% of the patients) as they could not come back for a repeated scan or because the 
repeated scan(s) was/were still of insufficient quality; in this case, data were disregarded and 
excluded from all analyses. The 83 participants included in the present study had high quality data. 
 
 2.3.2. Total Intracranial Volume (TIV). 
Individual TIV values were obtained from the T1-weighted images using the VBM5 toolbox 
implemented in the Statistical Parametric Mapping software (SPM5; Wellcome Trust Center for 
Neuroimaging, Institute of Neurology, London, England). 
2.3.3. Florbetapir PET. 
PET data were processed as described in reference [28]. Briefly, each individual T1-weighted MRI 
was segmented into gray and white matter using the VBM5 toolbox ( http://dbm.neuro.uni-
jena.de/vbm/vbm5-for-spm5/ ). These segments were used for partial volume effect correction of 
raw PET data using the PMOD software. Using the Statistical Parametric Mapping (SPM) software, 
resulting images were coregistered onto corresponding MRI and normalized into Montreal 
Neurological Institute (MNI) space using the deformation parameters defined from the VBM 
procedure. The mean Florbetapir value in the cerebellum GM was extracted for each subject from 
the normalized TEP images. Each Florbetapir image was then divided by its corresponding mean 
cerebellar value, resulting in Florbetapir-PET SUVr data. The global neocortical Florbetapir-PET 
SUVr value was then computed for each subject from the Florbetapir-PET SUVr data using a 
neocortex mask (including all regions but the cerebellum, hippocampus, amygdala and subcortical 
grey nuclei). 
2.4. Statistical analyses 
Raw volumes of each hippocampal subfield and of the whole hippocampus (corresponding to the 
sum of the three subfields) were first normalized by the TIV to account for inter-individual 
variability in head size (normalized volume = 1000 x raw volume / TIV) and then transformed into 
W-scores, i.e. age and gender-adjusted Z-scores [2]. W-scores provide information about the 
difference between a patient’s value and the value that would be expected in the control group for 
his/her age and gender. In the present study, the use of W-score is of particular interest because of 
the rather wide age range of the participants and significant age difference between aMCI and both 
 HC and SD groups (see Table 1). Due to the relative limited size of the patient groups, Kruskal-
Wallis non-parametric analyses of variance (ANOVAs) were then performed on hippocampal 
subfield and whole hippocampus W-scores, and when a significant effect of group was found 
(p<0.05), Mann-Whitney U tests were used for pairwise comparisons. 
As previous studies reported a stronger hemispheric asymmetry and an anterior predominance of 
hippocampal atrophy in SD compared with AD [11,12], complementary indices were calculated to 
characterize these gradients within each subfield. First, hemispheric asymmetry was measured as 
the absolute difference between left and right hippocampal volumes expressed as a percentage of 
the total volume (100 x |right volume – left volume| / bilateral hippocampal volume). Second, an 
index of anterior-posterior gradient was calculated as the percentage of each subfield volume 
located in the anterior hippocampus (100 x anterior volume / total hippocampal volume), with the 
anterior portion corresponding to the hippocampal head [29–31]. These indices were compared 
between HC, AD and SD using Kruskal-Wallis ANOVA and Mann-Whitney U tests. 
Discriminant analyses were performed to assess the ability of each hippocampal subfield and of the 
whole hippocampus volume to distinguish i) AD patients from HC, ii) aMCI patients from HC, iii) 
SD patients from AD. Areas Under the receiver operating characteristic Curve (AUC) of global 
hippocampus versus subfield volumes were then compared to test the hypothesis that subfield are 
more accurate than global hippocampal volumetry to discriminate between the groups. 
Finally, preliminary analyses were conducted to assess the impact of the presence of Aβ on the 
different hippocampal volumes. All AD patients (n=18) and 15 patients with aMCI (out of 17) 
underwent a Florbetapir PET scan and were classified using a previously determined Florbetapir 
neocortical SUVr of 1.1 (see reference [28]). All AD patients were classified as Aβ-positive and 9 
aMCI patients (60 % of aMCI patients who underwent Florbetapir-PET) were classified as Aβ-
positive. Aβ-positive and Aβ-negative aMCI did not differ in age, gender or education (all p-
values>0.8). Statistical analyses on hippocampal volumes included both Spearman’s correlation 
 between Aβ load and hippocampal atrophy within the 15 aMCI patients, and comparisons between 
Aβ-positive versus Aβ-negative aMCI, and between each subgroup and HC. For the latter analysis, 
because aMCI were significantly older than the whole HC group (see Table 1), a subgroup of age, 
gender and education-matched HC (n=28) was used. 
 
3. Results 
3.1. Atrophy of hippocampal subfields in patients. 
Comparisons of W-scores are illustrated in Figure 2. Briefly, the volume of the whole hippocampus 
was significantly decreased in all three patient groups as compared to HC (mean volume loss = -
12% for aMCI, -22% for AD and -17% for SD). In aMCI, atrophy was highly significant in CA1 (-
22%, p<0.001) and to a lesser extent in the subiculum (-17%, p=0.01). In AD, volume decreases 
were highly significant (p<0.001) for all three subfields, but atrophy in the other region (-17%) was 
significantly lower (p<0.005 using Wilcoxon rank-sum test) than in both CA1 and subiculum (both 
-27%). In the SD group, both CA1 and subiculum volumes were significantly reduced relative to 
HC (-27% and -24% respectively, both p<0.001). Similarly to the findings in the AD group, 
comparing degrees of atrophy (expressed as W-scores) between the three subfields in SD showed 
that both CA1 and subiculum were significantly more affected than the other subfield (both p<0.05 
Wilcoxon rank-sum test). None of the volumes differed between AD and SD patients (all p 
values>0.15). Note that the main results were unchanged when performing comparisons on raw 
volumes or TIV-normalized volumes instead of age- and gender-ajusted Wscores as presented here 
(see supplementary figure 2). 
3.2. Hemispheric asymmetry and anterior-posterior gradient in AD and SD. 
The results of the between-group comparisons of the hippocampal indices are reported in Table 2. 
Greater hemispheric asymmetry was found in SD patients compared to HC for all volumes (all p 
 values<0.03). Asymmetry was significantly stronger in SD than in AD for the whole hippocampus 
(p=0.001), subiculum (p=0.02), other (p=0.01) and a trend was found for CA1 (p=0.06). 
Finally, the anterior-posterior index was significantly lower in SD compared to both HC and AD 
for the whole hippocampus, CA1 and subiculum, indicating a predominance of atrophy in the 
anterior hippocampus in SD. 
3.3. Evaluation of diagnostic accuracy 
For the AD versus HC discrimination, the AUC of all subfields was significantly higher than 0.5 
(mean [95% CI]=0.92 [0.85-0.99] for CA1, 0.88 [0.76-1] for subiculum, 0.81 [0.67-0.94] for other) 
but none of them was significantly higher than that of the whole hippocampus (0.91 [0.78-1]). For 
the discrimination between HC and aMCI, the AUC of CA1 (0.88 [0.78-0.98]) was significantly 
higher than 0.5 and higher than the AUC of the whole hippocampus (0.76 [0.60-0.93], p=0.05; see 
Figure 3) whereas the subiculum AUC (0.74 [0.59-0.90]) was significantly higher than 0.5 but did 
not perform better than the whole hippocampus, and the AUC for the other subfields was not 
significantly different from 0.5 (0.53 [0.34-0.72]). Finally, none of the volume measurements 
allowed to separate AD from SD as none of the AUCs was significantly different from 0.5: 0.51 
[0.27-0.74] for CA1, 0.64 [0.43-0.85] for subiculum, 0.69 [0.45-0.94] for other, and 0.69 [0.47-
0.90] for the whole hippocampus. 
3.4. Volume of hippocampal subfields versus neocortical amyloid load in aMCI patients. 
A Kruskal-Wallis ANOVA with three groups (HC, Aβ-positive aMCI, Aβ-negative aMCI) was 
performed on TIV-normalized hippocampal measurements. A significant effect of group was found 
for CA1 (H=13.8; p=0.001), subiculum (H=5.99; p=0.05) and global hippocampus (H=5.98; 
p=0.05). Post-hoc analyses revealed that Aβ-positive aMCI had significantly lower CA1 (p<0.001), 
subiculum (p=0.01) and hippocampal volumes (p=0.01) as compared to HC, while Aβ-negative 
aMCI only showed lower CA1 volume (p=0.04) as compared to HC, as illustrated in Figure 4. The 
direct comparison between Aβ-positive aMCI and Aβ-negative aMCI did not show any significant 
 difference (all p values>0.25).  Similarly, none of the volumes significantly correlated with 
Florbetapir neocortical SUVr in the whole group of 15 aMCI (CA1: Spearman’s ρ= -0.34, p =0.22; 
subiculum ρ= -0.26, p=0.34; other ρ= -0.01, p=0.96; whole hippocampus ρ= -0.23, p=0.41). All the 
results remained unchanged when using W-scores instead of TIV-normalized volumes (data not 
shown). 
 
4. Discussion 
Using a high-resolution sequence on a 3T MRI scanner, hippocampal subfields were delineated in 
healthy controls and patients with aMCI, AD or SD. Analyses showed that the pathologies had a 
differential effect on the hippocampal subfields, with a preferential involvement (ie. stronger and 
earlier atrophy) of CA1 and subiculum. This pattern was not discriminant at the dementia stage as i) 
no differences were found between AD and SD and ii) hippocampal subfields did not perform 
better than the whole hippocampus in discriminating AD from HC. By contrast, at the aMCI stage, 
CA1 volume loss predominated and was found to better discriminate aMCI patients from HC than 
global hippocampal volume.  
4.1. Hippocampal subfield atrophy in AD 
The finding of a differential atrophy of the hippocampal subfields in AD, with a stronger and earlier 
alteration of CA1 and subiculum, is in agreement with neuropathological studies [16–19]. For 
instance, West et al [18] reported a reduction in the number of neurons in AD patients compared to 
HC of 68% in CA1, 47% in the subiculum and 25% in the hilus of the dentate gyrus. The higher 
vulnerability of CA1 neurons is likely to be at least partly due to the neurofibrillary pathology as 
the CA1 subfield is the first hippocampal area to be affected by NFT [16,17]. Moreover, several 
studies have reported a strong negative correlation between neuronal counts and NFT number in the 
CA1 subfield [32,33] suggesting that the progression of brain atrophy and NFT are strongly 
associated [34]. 
 Using a variety of neuroimaging approaches such as radial atrophy [35], large-deformation high-
dimensional brain mapping [36], voxel-based morphometry [37] or manual delineation [20], the 
predominance of atrophy in CA1 (and to a lesser extent in the subiculum) in patients with clinical 
AD or aMCI has already been shown in vivo. In the present study, we confirmed this point using a 
refined methodology in patients with both a clinical diagnosis of AD and a positive Florbetapir 
PET-scan. Our study showed that all subfields were atrophied at this AD dementia stage and 
subfield measurements were not more accurate than the global hippocampus in discriminating AD 
from HC. By contrast, and in agreement with previous volumetric studies [20,21,38], we showed 
that subfield measurements were more accurate than global hippocampal volumetry to differentiate 
aMCI from HC, highlighting the interest of these methods for early AD detection. However, 
discrepancies exist as regards to the area of largest difference between HC and aMCI patients (CA1 
[21], CA1-CA2 transition area [20] or subiculum [38]), probably reflecting variations in the 
anatomical landmarks used for subfield delineation as further discussed in previous publications 
[22,23] (see the method section 2.3.1 for further discussion). 
4.2. Comparison of the pattern of hippocampal atrophy in AD versus SD 
AD and SD patients did not differ in terms of subfield volumetry. Although the absence of 
significant difference could be due to a lack of statistical power, preferential atrophy of both CA1 
and subiculum were found in both groups and this finding is consistent with a recent surface-based 
study of the hippocampus in SD [39]. Yet, the pathological substrate of hippocampal atrophy in SD 
is not clear, notably because patients with SD can present with heterogeneous pathological features 
[40]. Despite this variability, a severe neuronal loss in the CA1 subfield together with a 
preservation of neurons in the dentate gyrus, consistent with our imaging findings, was reported 
independently of the histopathological subtypes [40].  
Contrastingly, hippocampal atrophy differed between SD and AD patients in terms of hemispheric 
and anterior-posterior asymmetry, in agreement with previous reports [11,12,14,15], and we 
 showed that these two gradients were mostly independent of subfields. Previous authors [11,14,15] 
hypothesized that this asymmetric nature of hippocampal atrophy in SD could partly explain the 
intriguing relative preservation of episodic memory in SD as compared to AD [41] in spite of 
similarly severe hippocampal atrophy [42]. According to these authors, the relatively spared 
hippocampal areas (posterior areas and most of the time the right hippocampus) in SD could 
therefore be sufficient to support essential episodic memory abilities [11,14,15]. Alternatively, it 
has been proposed [12] that differential alterations of cortical areas that are crucial for episodic 
memory, such as the posterior cingulate cortex (PCC) that shows a strong hypometabolism in AD 
but not in SD, are more likely to account for the differential alteration of episodic memory between 
AD and SD. Yet, these two hypothesis are not necessarily independent as hippocampal atrophy has 
been shown to induce PCC hypometabolism through a disconnection process in AD [43]. Besides, 
the connectivity of the hippocampus varies along its anterior-posterior axis, with the posterior part 
being more strongly connected to the PCC [44]. It is thus possible that the predominance of atrophy 
in the anterior hippocampus in SD at least partly accounts for differences in distant cortical 
alterations (e.g. the lack of PCC hypometabolism) compared to AD, themselves underlying 
differences in the cognitive deficits. This would also be consistent with the idea that SD and AD 
target two large-scale brain networks that would underlie different cognitive functions and 
differentially include anterior versus posterior hippocampi [45].  
4.3. Relationships between hippocampal subfield atrophy and Aβ in aMCI 
Because the presence of Aβ deposition significantly increases the likelihood of having AD 
pathology in patients with aMCI according to current diagnosis recommendations [8,9], we also 
investigated hippocampal subfield atrophy in aMCI patients as a function of Aβ load.  We did not 
find a significant influence of the presence of Aβ on the pattern of hippocampal subfield atrophy as 
both Aβ-positive and Aβ-negative aMCI showed a predominant atrophy of the CA1 subfield 
(Figure 4). However, these findings should be considered as preliminary given the small size of the 
 aMCI samples when dichotomized in Aβ-positive and Aβ-negative. Yet, this finding is in line with 
recent studies showing that AD-type atrophy and/or hypometabolism can be found in both Aβ-
negative healthy controls [46] and Aβ-negative MCI patients [47]. While it may reflect 
methodological issues related to biomarker measurements [48], it is possible that CA1 atrophy in 
Aβ-negative patients reflect non-AD pathophysiological processes. This would be consistent with 
the finding of CA1 atrophy in other disorders [2,49,50] and the idea that aMCI in Aβ-negative 
patients is unlikely due to AD etiology [9]. Alternatively, recent findings suggest that neuronal 
injury biomarkers known to be closely related to tau pathology such as hippocampal atrophy (see 
above), may occur independently and possibly prior to Aβ in the course of AD [51,52]. This would 
rather support hypotheses suggesting that tau pathology could occur independently from Aβ 
accumulation [53], than the amyloid hypothesis where tau-related neurodegeneration is supposed to 
appear downstream to Aβ. Further investigations are needed to test these hypotheses but also to 
replicate our findings regarding the relationships between hippocampal subfield atrophy and Aβ in 
a larger sample given the limited size of our aMCI subgroups. 
It should also be noted that subfield volumetry as performed in the present study only provides 
approximations of the exact volumes of the hippocampal subfields, based on anatomical landmarks 
derived from histological atlases (see the method section 2.3.1 for further discussion).  
4.4. Conclusion 
Overall, our findings in AD and SD are consistent with the topography of neuronal loss described 
in post-mortem studies as well as with previous imaging studies that used different methods. They 
suggest that hippocampal subfield volumetry is a promising biomarker for early AD detection at a 
predementia or even presymptomatic stage, especially with the widespread use of high-resolution 
MR sequences in the last years [20,22] and the on-going development of automatic subfield 
segmentation procedures [54,55]. Further studies are therefore needed to assess the diagnostic and 
 prognostic accuracies of this novel technique in larger samples and in comparison to other 
established AD biomarkers. 
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 FIGURES 
 
Figure 1. Illustration of hippocampal subfield delineation. 
 
Three regions were manually delineated within each hippocampus: CA1 (blue), subiculum (green) 
and other (pink). Subfields were delineated on 9 slices on average; for the purpose of illustration, 
examples are displayed on three slices along the anterior-posterior axis of the hippocampus. Images 
correspond to a healthy control (left), a patient with Alzheimer’s disease (middle) and a patient 
with semantic dementia (right). Images are in the neurological convention (right is right). 
Additional examples are available in supplementary figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Between-group comparisons of hippocampal measurements. 
 
Abbreviations: HC = healthy controls; aMCI = amnestic mild cognitive impairment; AD = 
Alzheimer’s disease; SD = semantic dementia. 
Volumes are expressed as W-scores (ie age- and gender-adjusted Z-scores as compared to the 
control group). 
Kruskall-Wallis ANOVA was significant for all regions and post-hoc tests were performed with the 
Mann-Whitney test (t: p<0.10; *: p<0.05; **: p<0.01; ***: p<0.001). 
 
 
 
 
 Figure 3. ROC Curve for CA1 and total hippocampal volume in aMCI patients versus HC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROC curves for CA1 (blue) and total hippocampal volume (gray) in the comparison between 
healthy controls (HC) and patients with amnestic Mild Cognitive Impairment (aMCI). The area 
under the curve (AUC) is significantly higher (p = 0.05) for CA1 (AUC = 0.881) than for total 
hippocampal volume (0.763). 
 
 
 
 
 
 
 
 
 Figure 4. CA1 atrophy in aMCI patients classified as Aβ-positive or Aβ-negative according to 
their neocortical Florbetapir SUVr. 
 
 
Abbreviations: HC = healthy controls; Aβ+ aMCI = βamyloid-positive patients with amnestic mild 
cognitive impairment; Aβ- aMCI = βamyloid-negative patients with amnestic mild cognitive 
impairment 
For this analysis, a subsample of 28 age-, gender-, and education-matched HC was selected. 
Kruskall-Wallis ANOVA was significant (p=0.001) and post-hoc tests were performed with the 
Mann-Whitney test (*: p<0.05; ***: p<0.001). 
 
 
 
 
 
 
 TABLES 
Table 1. Demographic characteristics of participants. 
 
 HC (n=40) aMCI (n=17) AD (n=18) SD (n=8) Group 
comparison 
Age  
Median (IQR) 
66 (56, 72) 72 (69, 75) 66 (58, 76) 62.5 (59.5, 65.5) pANOVA=0.027 
aMCI>HC; 
aMCI>SD 
Gender 
Females: n (%) 
23 (58%) 9 (53%) 12 (67%) 5 (63%) pChi-squared=0.86 
Years of education  
Median (IQR) 
12 (9.5, 15) 10 (8, 12) 10 (7, 14) 12 (5.8, 15.5) pANOVA=0.19 
MMSE 
Median (IQR) 
 
30 (29, 30) 27 (26, 28) 20.5 (20, 24) - pANOVA<0.001 
HC>aMCI>AD 
Mattis  
Median (IQR) 
143 (142, 144) 137 (134, 138)   123 (114, 128) 118 (111, 125.5) pANOVA<0.001 
HC>aMCI>AD, 
SD
a
 
 
Abbreviations: HC = healthy controls; aMCI = amnestic mild cognitive impairment; AD = 
Alzheimer’s disease; SD = semantic dementia; IQR = interquartile range; MMSE = mini-mental 
state examination; ANOVA = Analysis of variance. 
All variables were compared using non-parametric tests. 
a: Mattis scores were lower in AD and SD groups as compared to HC and aMCI but no difference 
was found between AD and SD. 
 
 
 
 
 
 
 
 
 
 Table 2. Hemispheric asymmetry and anterior-posterior gradients of subfield atrophy in AD 
and SD patients. 
 
 Values: median (IQR) Statistical comparisons 
 HC AD SD ANOVA HC / AD HC / SD AD / SD 
Hemispheric asymmetry 
CA1 5.4 
(1.8, 8.5) 
7.8 
(4.2, 17.0) 
15.3 
(13.1, 18.5) 
H = 14.7 
p < 10
-3
 
Z = 1.94 
p = 0.05 
Z = 3.67 
p < 10
-3
 
Z = 1.86 
p = 0.06 
Subiculum 3.8 
(1.6, 6.5) 
6.6 
(1.8, 8.1) 
17.7 
(12.7, 23.8) 
H = 16.1 
p < 10
-3
 
Z = 1.64 
p = 0.10 
Z = 3.91 
p < 10
-3
 
Z = 2.42 
p = 0.02 
Other 5.2 
(2.8, 9.8) 
5.1 
(1.9, 8.1) 
11.4 
(7.2, 14.4) 
H = 7.2 
p = 0.03 
Z = -0.82 
p = 0.42 
Z = 2.31 
p = 0.021 
Z = 2.53 
p = 0.01 
Global 
hippocampus 
2.1 
(1.2, 4.0) 
4.7 
(2.8, 7.1) 
14.2 
(11.2, 16.1) 
H = 27.1 
p < 10
-3
 
Z = 3.17 
p = 0.002 
Z = 4.41 
p < 10
-3
 
Z = 3.25 
p = 0.001 
Anterior-posterior gradient 
CA1 66.2 
(63.4, 70.0) 
66.6 
(59.7, 70.1) 
56.5 
(52.9, 57.6) 
H = 14.7 
p < 10
-3
 
Z = -0.33 
p = 0.74 
Z = -3.80 
p < 10
-3
 
Z = 3.08 
p = 0.002 
Subiculum 57.2 
(53.2, 61.5) 
60.1 
(53.3, 65.6) 
52.4 
(44.8, 54.9) 
H = 8.3 
p = 0.02 
Z = 1.02 
p = 0.31 
Z = 2.59 
p = 0.01 
Z = 2.47 
p = 0.01 
Other 62.8 
(57.5, 66.7) 
65.8 
(57.1, 70.4) 
59.7 
(55.5, 61.9) 
H = 3.03 
p = 0.22 
- - - 
Global 
hippocampus 
62.4 
(59.0, 65.1) 
64.6 
(58.2, 68.5) 
55.6 
(52.0, 59.0) 
H = 9.3 
p = 0.009 
Z = 0.60 
p = 0.55 
Z = 2.95 
p = 0.003 
Z = 2.53 
p = 0.01 
 
Abbreviations: HC = healthy controls; AD = Alzheimer’s disease; SD = semantic dementia; IQR = 
interquartile range. ANOVA were conducted with the Kruskall & Wallis H test and when 
significant (p<0.05), two-by-two comparisons were assessed with the Mann-Whitney test. 
Significant (p<0.05) results are shown in bold.  
Increased hemispheric asymmetry indicates a stronger left / right volume difference but not the 
direction of this difference. Increased anterior-posterior gradient index indicates an increase  in the 
volume of the anterior hippocampal compared to that of the total hippocampal volume. See main 
text (section 2.4) for further information. 
 
 
 SUPPLEMENTARY MATERIALS 
Supplementary figure 1 
 
 
Additional exemples of hippocampal subfield delineation in 3 patients with Alzheimer’s disease 
(AD), two patients with semantic dementia (SD) and a healthy control. For each individual, 
different slices are shown with and without annotations to enable a better visualization of the 
hippocampus. 
 
 
 
 
 
 Supplementary figure 2. Influence of the correction for total intracranial volume and 
demographic factors on group comparisons. 
 
 
 
Abbreviations: HC = healthy controls; aMCI = amnestic mild cognitive impairment; AD = 
Alzheimer’s disease; SD = semantic dementia; TIV = total intracranial volume. 
In the upper row, raw volumes were directly compared between groups. On the middle row, 
volumes were first normalized by the TIV using the following formula: normalized volume = 1000 
x raw volume / TIV. On the lower row, TIV-normalized volumes were transformed into W-scores 
(i.e. age and gender-adjusted Z-scores). This last row shows the same results as those presented in 
the main manuscript (figure 2) but are presented here for the sake of comparison with the other 
conditions. 
Pairwise comparisons were performed with the Mann-Whitney test (t: p<0.10; *: p<0.05; **: 
p<0.01; ***: p<0.001). Bars represent the median value for each group. 
